History

From Academic Roots to Industry Application

Founded in 1999 as a spin out from King’s College London, MedPharm translates academic pharmaceutical science into practical solutions for real-world drug development. We support sponsors with formulation development, analytical services, and manufacturing support across complex programs.

This science-led approach continues to shape how our teams evaluate programs, generate data, and make development decisions.

Global Expansion

As client needs and scientific capabilities evolved, MedPharm expanded to support a broader range of development and manufacturing activities.

Today, MedPharm operates facilities in Guildford, UK, and two sites in Durham, North Carolina. Together, these locations support pharmaceutical and biotechnology programs from early formulation through clinical and commercial manufacturing.

Ongoing investment in people, infrastructure, and technical expertise has enabled growth while preserving a strong scientific foundation.

Applied Innovation. Proven Results.

Since 1999, MedPharm has supported the development and approval of more than 85 marketed drug products across the United States, Europe, and Japan. This work is strengthened by proprietary technologies, including MedSpray®, and multidisciplinary teams with deep scientific and manufacturing expertise.

Together, these capabilities help translate complex pharmaceutical concepts into reliable, manufacturable, patient-ready products.

Key Milestones

2006
Opened our first standalone facility in Guildford, UK.
2015
Established a North American testing and development facility in Durham, North Carolina, to support growing client demand.
2018
Secured Ampersand Capital investment to support expansion.
2020
Expanded our Durham, North Carolina testing and development facility with a $4 million investment, enhancing formulation and analytical capabilities.
2021
Opened a custom-built 110,000 ft² manufacturing facility in Durham, North Carolina, to support large-scale clinical and commercial supply.
2023
Achieved FDA approval of PAS, reinforcing our commitment to regulatory excellence.
2023
Successfully shipped our first commercial drug product.
2024
Strategic investment from Bourne Partners. Merged with Tergus Pharma.
2025
Durham, North Carolina cGMP commercial manufacturing facility completed a U.S. FDA inspection, receiving an NAI classification.
History

Ask A Scientist



Science moves fast.
So do we.
Ask our experts now.


Get A Quote



Big ideas deserve fast action.
Let’s kick off your quote today.